Pharmaceutical preparations, namely, prescription drugs for the treatment of multiple myeloma by slowing the growth of cancer cells, prescription drugs for the treatment of multiple myeloma by stopping the growth of cancer cells, prescription drugs for palliative treatment of patients with multiple myeloma, and prescription drugs for use as an iron chelator for the treatment of patients with transfusion iron overload due to thalassemia syndromes, prescription drugs for the treatment of iron-associated neurodegenerative conditions, namely, Parkinson's disease and neurodegeneration with brain iron accumulation, in particular, pantothenate kinase-associated neurodegeneration
Pharmaceuticals